The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 340:62 January 7, 1999 Number 1
NextNext

Inappropriate Use of Enoxaparin in the Treatment of Deep-Vein Thrombosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: Low-molecular-weight heparins such as enoxaparin offer advantages over unfractionated heparin in the treatment of venous thromboembolism.1 For such indications, enoxaparin is currently approved only as prophylaxis against venous thromboembolism in patients who undergo orthopedic surgery. Approval by the Food and Drug Administration (FDA) is pending for the treatment of venous thromboembolism. Nevertheless, the off-label use of enoxaparin to treat patients with venous thromboembolism is increasing. I recently encountered two cases that illustrate the inappropriate use of the drug to treat venous thromboembolism.

Four days after foot surgery, deep-vein thrombosis developed in a 48-year-old woman. Treatment with 30 . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.